Zacks Research Estimates Neogen's Q2 Earnings (NASDAQ:NEOG)

Neogen Co. (NASDAQ:NEOG - Free Report) - Investment analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for shares of Neogen in a research report issued to clients and investors on Thursday, January 2nd. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.11 for the quarter, down from their previous estimate of $0.12. The consensus estimate for Neogen's current full-year earnings is $0.50 per share. Zacks Research also issued estimates for Neogen's FY2027 earnings at $0.72 EPS.

Other analysts have also issued reports about the company. StockNews.com raised Neogen to a "sell" rating in a research report on Monday, September 30th. Guggenheim assumed coverage on Neogen in a report on Thursday, December 19th. They set a "buy" rating and a $15.00 price objective on the stock.

Neogen Stock Up 3.9 %

NEOG stock traded up $0.48 during trading on Monday, reaching $12.73. The stock had a trading volume of 1,990,053 shares, compared to its average volume of 1,786,083. The company has a current ratio of 4.41, a quick ratio of 2.79 and a debt-to-equity ratio of 0.28. The firm has a fifty day moving average price of $13.65 and a 200 day moving average price of $15.19. The company has a market capitalization of $2.76 billion, a P/E ratio of -115.73 and a beta of 1.23. Neogen has a 1-year low of $11.46 and a 1-year high of $19.88.

Neogen (NASDAQ:NEOG - Get Free Report) last posted its quarterly earnings data on Thursday, October 10th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). The firm had revenue of $217.00 million for the quarter, compared to analysts' expectations of $215.05 million. Neogen had a negative net margin of 2.58% and a positive return on equity of 2.80%. The company's revenue for the quarter was down 5.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.11 EPS.

Insider Transactions at Neogen

In other news, CEO John Edward Adent bought 14,500 shares of Neogen stock in a transaction on Friday, October 11th. The shares were bought at an average price of $13.80 per share, with a total value of $200,100.00. Following the acquisition, the chief executive officer now directly owns 216,477 shares in the company, valued at approximately $2,987,382.60. This represents a 7.18 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.13% of the company's stock.

Institutional Investors Weigh In On Neogen

Institutional investors and hedge funds have recently made changes to their positions in the company. Citigroup Inc. raised its holdings in shares of Neogen by 129.1% during the third quarter. Citigroup Inc. now owns 231,833 shares of the company's stock worth $3,897,000 after purchasing an additional 130,641 shares during the period. American Capital Management Inc. raised its stake in Neogen by 36.5% during the third quarter. American Capital Management Inc. now owns 3,414,700 shares of the company's stock worth $57,401,000 after acquiring an additional 913,604 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in Neogen in the second quarter worth about $5,714,000. Oppenheimer Asset Management Inc. boosted its stake in Neogen by 39.8% in the second quarter. Oppenheimer Asset Management Inc. now owns 103,611 shares of the company's stock valued at $1,619,000 after acquiring an additional 29,489 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Neogen by 17.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 38,166 shares of the company's stock valued at $642,000 after purchasing an additional 5,804 shares during the last quarter. 96.73% of the stock is owned by institutional investors and hedge funds.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.